Cautious Approach Needed to HTPs' Harm Reduction Claims: Study

Nov.11.2022
Cautious Approach Needed to HTPs' Harm Reduction Claims: Study
A new study warns that current evidence on heated tobacco products (HTPs) doesn't meet standards, and claims of harm reduction should be taken with caution.

The author of a new study published in "Tobacco Control" has stated that the quality of existing evidence regarding heated tobacco products (HTPs) is insufficient and policymakers should be cautious about claims of harm reduction.


In recent years, HTPs have become popular and supporters insist that they pose less harm to health than traditional cigarettes. However, researchers from the University of Bath argue that the evidence supporting these claims largely fails to account for real-world usage and is subject to a high risk of bias.


In their analysis of 40 publicly disclosed HTP clinical trials, 29 of which were affiliated with or sponsored by the tobacco industry, researchers determined that the majority of existing clinical trials have a "high risk of bias" based on their methods and study design.


The most common reason for research to be at high risk of bias is performance bias, which occurs when participants and those conducting the test are aware of the intervention measures being assigned. Additionally, failure to report all result data from the trial measurements is a flaw known as selective reporting bias.


The author believes that the existence of biases has damaged the validity of the experiment, which may lead to an overestimation of the effectiveness of HTP. They also found further limitations in the experiment, including a short duration, restrictive conditions that do not reflect real-world situations, and a lack of relevant comparators, such as e-cigarettes.


The tobacco control research group in Bath says that more detailed independent studies are necessary to evaluate the short and long-term health effects of HTPs.


At the same time, they believe that consumers should be wary of claims of harm reduction, and policymakers and regulators should carefully consider the role of these trials when making decisions surrounding HTPs.


In recent years, there has been significant development in the heated tobacco market in the UK and around the world. According to Sophie Braznell, Chief Researcher at Bath Health Authority, this growth is premised on the notion that these products are healthier than traditional cigarettes.


Our analysis indicates that the situation is far from clear. Clinical trials used by the tobacco industry to support these claims are often inadequate in terms of research methods and reporting, and most are somehow linked to the tobacco industry.


As more and more consumers are turning away from cigarettes and towards these new generation products, there is a need for better evidence to evaluate their current and future health impact. At the same time, the jury is still out on their potential benefits.


The findings related to clinical trials on heated tobacco products are very important, and we need to remain vigilant about the health claims made," added Gemma Taylor, a co-author of the research report from the Addiction and Mental Health Group and Department of Psychology at the University of Bath.


However, at the same time, it is important to note the clear distinction between "heated tobacco products" and "electronic cigarettes". Consumers and health policy makers must not equate the potential benefits of electronic cigarettes in helping people quit smoking with heated tobacco products.


Statement:


This article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in the translation skills, the translated article may differ from the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all statements and positions related to domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Bonnie Herzog:U.S. nicotine market seen at about $67B in revenue by 2035 as smoke-free expands
Bonnie Herzog:U.S. nicotine market seen at about $67B in revenue by 2035 as smoke-free expands
Goldman Sachs Managing Director Bonnie Herzog said the U.S. nicotine market is attractive and growing, with total revenue projected to reach about $67 billion by 2035. She expects cigarettes to account for a smaller share of revenue (47%) as smoke-free revenue expands and becomes a key driver of industry profit growth. Herzog said smoke-free products represent about 48% of U.S. nicotine volumes today and could rise to roughly 75% by 2035.
Mar.04 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
The UK government plans to expand the scope of its e-cigarette ban to include playgrounds, off-campus areas, and areas outside hospitals.
The UK government plans to expand the scope of its e-cigarette ban to include playgrounds, off-campus areas, and areas outside hospitals.
Government plans would ban vaping in cars carrying children and restrict smoking, vaping and heated tobacco in settings including playgrounds and outside schools across England, subject to a 12-week public consultation. The proposals also say indoor spaces where smoking is already banned would become vape- and heated-tobacco-free, and areas outside hospitals would be included.
Feb.13 by 2FIRSTS.ai
Illegal Trade in Tobacco and E-Cigarettes Continues to Rise in Germany, BVTE and BDZ Call for Enforceable Regulation
Illegal Trade in Tobacco and E-Cigarettes Continues to Rise in Germany, BVTE and BDZ Call for Enforceable Regulation
BVTE and BDZ said at a joint press conference in Berlin on March 10 that illegal trade in tobacco products, e-cigarettes and other nicotine products continues to grow in Germany, posing challenges to the rule of law, youth protection, consumer protection and state fiscal authority. The groups said there is still no reliable overall statistic for the illegal trade in tobacco products, e-cigarettes, nicotine pouches and oral nicotine products.
Mar.12 by 2FIRSTS.ai
Iowa Targets Smoking Products With Tax Plan: Cigarettes to National Average, 15% Tax on Vapes and Consumable Hemp
Iowa Targets Smoking Products With Tax Plan: Cigarettes to National Average, 15% Tax on Vapes and Consumable Hemp
Iowa Gov. Kim Reynolds is proposing higher taxes on cigarettes and new taxes on vaping and consumable hemp products, arguing tobacco use is a key driver of lung cancer. The proposal comes as University of Iowa researchers release preliminary findings suggesting Iowa’s late-stage lung cancer burden is higher—and improving more slowly—than in neighboring states.
Feb.06 by 2FIRSTS.ai
KT&G Approves Plan to Establish Guatemala Branch as First Local Base in Central and South America
KT&G Approves Plan to Establish Guatemala Branch as First Local Base in Central and South America
KT&G has approved a plan to establish a branch in Guatemala, which will serve as its first local base in Central and South America. The company is currently preparing office space, staffing, and operating systems. KT&G said the branch is intended to secure a regional distribution base and will focus on local channel management and new sales channel expansion. Meanwhile, overseas cigarette revenue in 2025 exceeded the domestic share for the first time.
Mar.09 by 2FIRSTS.ai